TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030

Benzinga Logo Benzinga By Neeraj Chawla
Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030

Kuick Research released a comprehensive study on the US Orphan Drug Market, projecting market opportunities exceeding $190 billion by 2030, with over 850 orphan drugs in clinical trials and 500 marketed orphan drugs, highlighting significant investment potential in rare disease therapeutics.

Insights
ORCL   neutral

Briefly mentioned in passing without substantive discussion


MRK   positive

Keytruda generated nearly $29.4 billion in global revenue in 2024, demonstrating successful expansion from an orphan drug designation to a blockbuster therapeutic